Lyme Disease vaccine shows 74% efficacy but misses key statistical goal.
Pfizer and Valneva said Monday their Lyme disease vaccine showed more than 70% efficacy in a late-stage study, even as it missed its main goal. U.S.-listed shares of the French drugmaker tumbled more than 35% in premarket trading following the update, while Pfizer was flat. The vaccine demonstrated 73.2% efficacy starting 28 days after the …